Description

This opportunity funds the development and validation of established and novel biomarkers that address critical clinical needs in Alzheimer’s disease and related dementias. The focus is on biomarkers with a defined context of use, clear advantages over existing options, and a credible path to commercialization or clinical adoption. High-priority areas include neuroinflammation, synaptic integrity, autophagy, TDP-43, neuronal loss, vascular injury, mitochondrial function, protein misfolding, oxidative stress, white matter changes, Lewy body dementia, and other novel targets with strong biological rationale. Supported modalities include PET ligands, CSF biomarkers, MRI, and advanced EEG approaches. Projects must demonstrate clinical utility, innovation, and translational potential.